Yi Li1,2, Yujun Xu2, Xinghan Liu2, Xin Yan1, Yue Lin1, Qian Tan3, Yayi Hou4,5. 1. Department of Burns and Plastic Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210093, People's Republic of China. 2. The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing, 210093, People's Republic of China. 3. Department of Burns and Plastic Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210093, People's Republic of China. smmutanqian@sina.com. 4. The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing, 210093, People's Republic of China. yayihou@nju.edu.cn. 5. Jiangsu Key Laboratory of Molecular Medicine, Nanjing University, Nanjing, 210093, People's Republic of China. yayihou@nju.edu.cn.
Abstract
BACKGROUND: Skin wounds in diabetic patients hardly recover. Accumulating evidence has shown that mammalian target of rapamycin (mTOR) pathway and myeloid-derived suppressor cells (MDSCs) are involved in inflammatory-related response. INK128 is a novel mTOR kinase inhibitor in clinical development. However, the exact roles of MDSCs and INK128 in healing wound of diabetic patients are unclear. METHODS: Mice models of normal, diabetic, and diabetic+INK128 were constructed. Bone marrow (BM)-derived macrophages and RAW264.7 cell line co-cultured with MDSCs, which were induced at different conditions. Flow cytometry, western blot, quantitative real-time PCR, and immunohistochemical analysis were performed. RESULTS: Diabetic mice (DM) had a slower recovery rate, thinner epidermis and dermis, and less blood vessels than those of normal mice. MDSCs were abnormally accumulated in DM, mTOR was activated in MDSCs of DM, and the cells were treated with high glucose. Moreover, mTOR signaling inhibitor INK128 could promote wound healing through reducing the MDSCs. MDSC function was disordered in DM and high-glucose environments, while INK128 could help retrieve their function. Furthermore, high glucose and other factors in DM could promote M-MDSC differentiation to M1 pro-inflammatory macrophage cells, thus inhibiting wound healing. The differentiation, which was dependent on mTOR signaling, could be reversed by INK128. CONCLUSION: INK128 is potential to be developed as a clinical strategy to promote wound healing of diabetic patients.
BACKGROUND: Skin wounds in diabetic patients hardly recover. Accumulating evidence has shown that mammalian target of rapamycin (mTOR) pathway and myeloid-derived suppressor cells (MDSCs) are involved in inflammatory-related response. INK128 is a novel mTOR kinase inhibitor in clinical development. However, the exact roles of MDSCs and INK128 in healing wound of diabetic patients are unclear. METHODS: Mice models of normal, diabetic, and diabetic+INK128 were constructed. Bone marrow (BM)-derived macrophages and RAW264.7 cell line co-cultured with MDSCs, which were induced at different conditions. Flow cytometry, western blot, quantitative real-time PCR, and immunohistochemical analysis were performed. RESULTS: Diabetic mice (DM) had a slower recovery rate, thinner epidermis and dermis, and less blood vessels than those of normal mice. MDSCs were abnormally accumulated in DM, mTOR was activated in MDSCs of DM, and the cells were treated with high glucose. Moreover, mTOR signaling inhibitor INK128 could promote wound healing through reducing the MDSCs. MDSC function was disordered in DM and high-glucose environments, while INK128 could help retrieve their function. Furthermore, high glucose and other factors in DM could promote M-MDSC differentiation to M1 pro-inflammatory macrophage cells, thus inhibiting wound healing. The differentiation, which was dependent on mTOR signaling, could be reversed by INK128. CONCLUSION: INK128 is potential to be developed as a clinical strategy to promote wound healing of diabetic patients.
Authors: Julio C Fernández-Ruiz; Julia C Galindo-De Ávila; Margarita L Martínez-Fierro; Idalia Garza-Veloz; Alberto R Cervantes-Villagrana; Monica A Valtierra-Alvarado; Carmen J Serrano; Mariana H García-Hernández; José A Enciso-Moreno; Julio E Castañeda-Delgado Journal: J Diabetes Res Date: 2019-12-12 Impact factor: 4.011
Authors: Thomas Welte; Ik Sun Kim; Lin Tian; Xia Gao; Hai Wang; June Li; Xue B Holdman; Jason I Herschkowitz; Adam Pond; Guorui Xie; Sarah Kurley; Tuan Nguyen; Lan Liao; Lacey E Dobrolecki; Lan Pang; Qianxing Mo; Dean P Edwards; Shixia Huang; Li Xin; Jianming Xu; Yi Li; Michael T Lewis; Tian Wang; Thomas F Westbrook; Jeffrey M Rosen; Xiang H-F Zhang Journal: Nat Cell Biol Date: 2016-05-16 Impact factor: 28.824
Authors: Mohamed Badawi; Jihye Kim; Anees Dauki; Dhruvitkumar Sutaria; Tasneem Motiwala; Ryan Reyes; Nissar Wani; Shamalatha Kolli; Jinmai Jiang; Christopher C Coss; Samson T Jacob; Mitch A Phelps; Thomas D Schmittgen Journal: Oncotarget Date: 2018-05-25